Stable and reliable funding for premium support is key to helping the most vulnerable countries manage the growing financial ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

CuraTeQ Biologics s.r.o., announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending marketing authorisation of Dazublys®, its trastuzumab biosimilar, for the ...